Sixth Confirmed Response in Pancreatic Cancer Trial
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- FDA Fast Track Designation for Narmafotinib
- Fifth Confirmed Response in ACCENT Trial
- Amplia Receives R&D Tax Rebate Totalling $3.2 Million
- Granting of Key Patent in Europe and Japan
- Additional Patient Response in Pancreatic Cancer Trial
Later from Amplia Therapeutics
- Interim Data From Accent Pancreatic Cancer Trial
- Amplia to Raise up to $13m for ACCENT and US Trials
- Capital Raise Presentation
- Amplia Successfully Completes Institutional Offer
- Security Class Suspension from Quotation
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics